Core Viewpoint - Xuan Bamboo Biotech-B (02575.HK) announced that its self-developed innovative drug, Pirlosilide Tablets (brand name: XuanYueNing®), has been included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog (2025) [1] Group 1 - The inclusion of XuanYueNing® in the 2025 National Basic Medical Insurance Catalog will officially take effect on January 1, 2026 [1] - This outcome of the medical insurance negotiation will enhance the affordability and accessibility of XuanYueNing® for patients, facilitating its market promotion and increasing sales scale [1] - The company plans to actively cooperate in implementing the medical insurance policy, continue to promote hospital access, expand core markets, and increase market coverage to improve patient access to medication [1]
轩竹生物-B(02575.HK)：创新药轩悦宁®首次纳入国家基本医保药品目录